16782734

Source:http://linkedlifedata.com/resource/pubmed/id/16782734

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003872, umls-concept:C0018759, umls-concept:C0030705, umls-concept:C0087111, umls-concept:C0220812, umls-concept:C0243076, umls-concept:C0686907, umls-concept:C0812246, umls-concept:C1456820
pubmed:issue	8
pubmed:dateCreated	2006-7-24
pubmed:abstractText	Tumour necrosis factor (TNF) has been shown to improve the outcomes in patients with psoriatic arthritis (PsA). We estimate the long-term impact on health status of prescribing the TNF antagonist etanercept, and evaluate the cost-effectiveness in a health economic model.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100883501
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents..., http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor, http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1462-0324
pubmed:author	pubmed-author:AraRR, pubmed-author:BansbackN JNJ, pubmed-author:BarkhamNN, pubmed-author:BrennanAA, pubmed-author:ConwayPP, pubmed-author:EmeryPP, pubmed-author:FraserA DAD, pubmed-author:ReynoldsAA
pubmed:issnType	Print
pubmed:volume	45
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1029-38
pubmed:dateRevised	2007-9-6
pubmed:meshHeading	pubmed-meshheading:16782734-Adult, pubmed-meshheading:16782734-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:16782734-Antirheumatic Agents, pubmed-meshheading:16782734-Arthritis, Psoriatic, pubmed-meshheading:16782734-Cost-Benefit Analysis, pubmed-meshheading:16782734-Disability Evaluation, pubmed-meshheading:16782734-Drug Therapy, Combination, pubmed-meshheading:16782734-Female, pubmed-meshheading:16782734-Health Care Costs, pubmed-meshheading:16782734-Humans, pubmed-meshheading:16782734-Immunoglobulin G, pubmed-meshheading:16782734-Male, pubmed-meshheading:16782734-Middle Aged, pubmed-meshheading:16782734-Models, Econometric, pubmed-meshheading:16782734-Quality-Adjusted Life Years, pubmed-meshheading:16782734-Receptors, Tumor Necrosis Factor, pubmed-meshheading:16782734-Treatment Failure, pubmed-meshheading:16782734-Treatment Outcome, pubmed-meshheading:16782734-Tumor Necrosis Factor-alpha
pubmed:year	2006
pubmed:articleTitle	Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
pubmed:affiliation	Health Economics and Decision Science, School of Health and Related Research ScHARR, University of Sheffield, Regent Court, 40 Regent Street, Sheffield S1 4DA, UK. n.j.bansback@sheffield.ac.uk
pubmed:publicationType	Journal Article